BR112012014066A2 - preparações de combinações com exossomos e corticosteróide - Google Patents

preparações de combinações com exossomos e corticosteróide

Info

Publication number
BR112012014066A2
BR112012014066A2 BR112012014066A BR112012014066A BR112012014066A2 BR 112012014066 A2 BR112012014066 A2 BR 112012014066A2 BR 112012014066 A BR112012014066 A BR 112012014066A BR 112012014066 A BR112012014066 A BR 112012014066A BR 112012014066 A2 BR112012014066 A2 BR 112012014066A2
Authority
BR
Brazil
Prior art keywords
exosomes
corticosteroids
combination preparations
combined therapy
diseases
Prior art date
Application number
BR112012014066A
Other languages
English (en)
Inventor
Reinecke Julio
Wehling Peter
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of BR112012014066A2 publication Critical patent/BR112012014066A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

preparações de combinações com exossomos e corticosteróide. a presente invenção refere-se a composições farmacêuticas para uma terapia combinada com um corticosteróide e exossomos. por meio da terapia combinada, doenças, tais como artrose, artrite e/ou doenças degenerativas da coluna vertebral podem ser tratadas.
BR112012014066A 2009-12-10 2010-12-10 preparações de combinações com exossomos e corticosteróide BR112012014066A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009057495 2009-12-10
PCT/EP2010/069426 WO2011082950A1 (de) 2009-12-10 2010-12-10 Kombinationspräparate mit exosomen und corticosteroid

Publications (1)

Publication Number Publication Date
BR112012014066A2 true BR112012014066A2 (pt) 2017-04-04

Family

ID=43707934

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012013888A BR112012013888A2 (pt) 2009-12-10 2010-12-10 preparados de combinação com antagonista de citocina e corticosteroide
BR112012014066A BR112012014066A2 (pt) 2009-12-10 2010-12-10 preparações de combinações com exossomos e corticosteróide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012013888A BR112012013888A2 (pt) 2009-12-10 2010-12-10 preparados de combinação com antagonista de citocina e corticosteroide

Country Status (22)

Country Link
US (3) US9724391B2 (pt)
EP (2) EP2437748B8 (pt)
JP (2) JP5907886B2 (pt)
KR (2) KR20120109542A (pt)
CN (2) CN107096031A (pt)
AU (2) AU2010340999B2 (pt)
BR (2) BR112012013888A2 (pt)
CA (2) CA2781223C (pt)
CY (2) CY1118081T1 (pt)
DE (1) DE202009017772U1 (pt)
DK (2) DK2437747T3 (pt)
ES (2) ES2594766T3 (pt)
HR (2) HRP20161268T1 (pt)
HU (2) HUE030460T2 (pt)
LT (2) LT2437747T (pt)
MX (2) MX2012006206A (pt)
PL (2) PL2437748T3 (pt)
PT (2) PT2437747T (pt)
RS (2) RS55251B1 (pt)
RU (2) RU2557897C2 (pt)
SI (2) SI2437747T1 (pt)
WO (2) WO2011082951A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189475A9 (en) * 2009-12-10 2017-07-06 Orthogen Ag Combination preparation comprising a cytokine antagonist and corticosteroid
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
CN104673749B (zh) * 2015-02-12 2017-10-20 江苏大学 一种粒细胞样髓源性抑制细胞来源exosomes及其应用
TW201722443A (zh) * 2015-11-13 2017-07-01 奧爾托金公司 對老化相關病症有效之醫藥製劑
CR20190139A (es) * 2016-08-17 2019-06-03 Orthogen Ag Preparación farmacéutica anti envejecimiento
EP3500278A4 (en) 2016-08-19 2020-04-01 Calimmune, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS
WO2018056481A1 (ko) * 2016-09-23 2018-03-29 ㈜프로스테믹스 면역 억제 및 항염증성 조성물
AU2017371043B2 (en) * 2016-12-07 2022-12-15 University Of Florida Research Foundation, Incorporated IL-1Ra cDNAs
CN108175759B (zh) * 2016-12-08 2021-03-19 暨南大学 一种抗肿瘤靶向给药系统及其制备方法与应用
EA038300B1 (ru) * 2017-04-18 2021-08-06 Юниверсити Оф Флорида Рисерч Фаундейшен, Инкорпорейтед Кднк il-1ra
CN108619114B (zh) * 2018-05-02 2020-08-11 东南大学 一种负载地塞米松的巨噬细胞源微囊泡及其制备方法和应用
CN109078171A (zh) * 2018-09-10 2018-12-25 因之彩生物科技（武汉）有限公司 一种外用组合物及其应用以及外用治疗剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2793159A (en) * 1955-03-09 1957-05-21 Upjohn Co Stable hydrocortisone solution
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
KR20040010739A (ko) 1996-02-09 2004-01-31 암젠 인코포레이티드 인터루킨-1 수용체 길항물질을 포함하는 융합 단백질 및 이를 포함하는 제약학적 조성물
US7026445B2 (en) * 1997-02-06 2006-04-11 Genetics Institute, Llc Human SDF-5 protein and compositions
CH694074A5 (de) 1997-08-16 2004-07-15 Orthogen Gentechnologie Gmbh Verfahren zur Herstellung von therapeutisch wirksamen Proteinen.
DE19903876B4 (de) 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
DE10213780A1 (de) 2002-03-22 2003-11-27 Orthogen Ag Verfahren und Mittel zur Herstellung therapeutisch interessanter Blutzusammensetzungen
BRPI0512814A (pt) 2004-07-01 2008-04-08 Univ Pittsburgh Of The Commmmo exosomas imunossupressivas
DE102004036840B4 (de) 2004-07-29 2012-04-19 Orthogen Ag Verfahren und Mittel zur Gewinnung von thrombocytenreichem Plasma
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
EP1906960A4 (en) 2005-07-11 2010-03-10 Astrazeneca Ab NEW COMBINATION 1
US7292185B2 (en) * 2005-10-04 2007-11-06 Csi Wireless Inc. Attitude determination exploiting geometry constraints
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
DE102006005016A1 (de) 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
AU2010341000B2 (en) 2014-08-14
DK2437747T3 (en) 2016-10-24
JP5907886B2 (ja) 2016-04-26
CA2781576A1 (en) 2011-07-14
CY1118044T1 (el) 2017-05-17
RS55251B1 (sr) 2017-02-28
PL2437748T3 (pl) 2017-09-29
EP2437747B8 (de) 2016-10-19
WO2011082950A1 (de) 2011-07-14
HRP20161279T1 (hr) 2016-12-02
WO2011082951A1 (de) 2011-07-14
CN102652020A (zh) 2012-08-29
KR20120109542A (ko) 2012-10-08
CN107096031A (zh) 2017-08-29
JP2013513582A (ja) 2013-04-22
MX2012006430A (es) 2012-07-30
EP2437747B1 (de) 2016-08-31
JP5984674B2 (ja) 2016-09-06
RU2526161C2 (ru) 2014-08-20
RU2557897C2 (ru) 2015-07-27
ES2594766T3 (es) 2016-12-22
CA2781223C (en) 2016-02-16
DE202009017772U1 (de) 2011-04-21
CY1118081T1 (el) 2017-06-28
RS55217B1 (sr) 2017-02-28
HUE029979T2 (en) 2017-04-28
CA2781223A1 (en) 2011-07-14
KR20120107108A (ko) 2012-09-28
US20120237587A1 (en) 2012-09-20
PT2437748T (pt) 2016-10-14
AU2010341000A1 (en) 2012-06-21
AU2010340999A1 (en) 2012-06-21
US20190038719A1 (en) 2019-02-07
PT2437747T (pt) 2016-10-18
DK2437748T3 (en) 2016-10-24
EP2437748A1 (de) 2012-04-11
DK2437748T5 (en) 2016-12-05
US10537614B2 (en) 2020-01-21
BR112012013888A2 (pt) 2017-03-07
HUE030460T2 (en) 2017-05-29
US20130164303A2 (en) 2013-06-27
PL2437747T3 (pl) 2017-01-31
HRP20161268T1 (hr) 2016-11-04
MX2012006206A (es) 2012-06-28
EP2437747A1 (de) 2012-04-11
EP2437748B1 (de) 2016-08-31
SI2437748T1 (sl) 2016-12-30
EP2437748B8 (de) 2016-10-19
US8828946B2 (en) 2014-09-09
CA2781576C (en) 2016-02-09
SI2437747T1 (sl) 2016-12-30
AU2010340999B2 (en) 2014-08-14
LT2437747T (lt) 2016-10-25
CN102655868A (zh) 2012-09-05
KR101786444B1 (ko) 2017-10-18
US20120237525A1 (en) 2012-09-20
RU2012128776A (ru) 2014-01-20
JP2013513583A (ja) 2013-04-22
LT2437748T (lt) 2016-11-10
US9724391B2 (en) 2017-08-08
ES2594896T3 (es) 2016-12-23
RU2012128877A (ru) 2014-01-20

Similar Documents

Publication Publication Date Title
BR112012014066A2 (pt) preparações de combinações com exossomos e corticosteróide
EP4219713A3 (en) Products and compositions
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
BR112012008282A2 (pt) anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MY161088A (en) Agonists of gpr40
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
BR112012005957A2 (pt) compostos tricíclicos e usos farmacêuticos dos mesmos
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
BR112012022337A2 (pt) composição e respectivos método de preparação e uso de quantidade eficaz
BR112016003293A2 (pt) anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos
MX2013011421A (es) Derivados de pirazolo-pirimidina.
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UY33219A (es) Cetoenoles cíclicos para terapias
MY170604A (en) Inhibitors of apoptosis and uses thereof
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL